Acyclic And Contains At Least One Carbon Atom Between The Phosphorus Atoms Patents (Class 514/108)
-
Publication number: 20140274905Abstract: The present invention generally relates to methods of modulating Cav1.2 channels and Cav1.2 channel activators.Type: ApplicationFiled: March 13, 2014Publication date: September 18, 2014Applicant: Duke UniversityInventors: Geoffrey S. Pitt, Adam S. Barnett, Xinhe Yin
-
Publication number: 20140274967Abstract: This invention relates generally to polyisoprenyl phosphonate derivatives pharmaceutical compositions comprising polyisoprenyl phosphonate derivatives, and uses thereof.Type: ApplicationFiled: March 15, 2013Publication date: September 18, 2014Applicant: COYOTE PHARMACEUTICALS, INC.Inventors: William Boyle, Naoki Nakayama
-
Publication number: 20140271813Abstract: The present invention relates to a liposomal formulation containing a therapeutic agent and a process for producing the formulation. The liposomal formulation comprises particular characteristics that enhance uniformity and stability of the formulation. The manufacturing process is a novel process that produces a liposomal formulation of a uniform size with many desirable properties that may be independently controlled. Further, the invention relates to a liposome formulation made in accordance with the manufacturing process.Type: ApplicationFiled: March 14, 2013Publication date: September 18, 2014Applicant: BIOrest Ltd.Inventors: Yoram RICHTER, Yehuda ZELIG, Omar ELMALAK, Dror EYAL
-
Publication number: 20140271825Abstract: The present invention provides liposomes loaded with chelating agents, pharmaceutical formulations including these liposomes and methods of making chelating agent liposomes. Because the chelating agents are loaded in the liposome with high efficiencies, the liposomes are of use in treatment of metal ion overload in subjects. The liposomes can include two or more different chelating agents of different structures and affinities for metal ions.Type: ApplicationFiled: March 14, 2014Publication date: September 18, 2014Inventors: Mark E. HAYES, Charles O. NOBLE, Francis C. SZOKA, JR.
-
Publication number: 20140274953Abstract: The described invention provides an ex vivo dynamic multiple myeloma (MM) cancer niche contained in a microfluidic device. The dynamic MM cancer niche includes (a) a three-dimensional tissue construct containing a dynamic ex vivo bone marrow (BM) niche, which contains a mineralized bone-like tissue containing viable osteoblasts self-organized into cohesive multiple cell layers and an extracellular matrix secreted by the viable adherent osteoblasts; and a microenvironment dynamically perfused by nutrients and dissolved gas molecules; and (b) human myeloma cells seeded from a biospecimen composition comprising mononuclear cells and the multiple myeloma cells. The human myeloma cells are in contact with osteoblasts of the BM niche, and the viability of the human myeloma cells is maintained by the MM cancer niche.Type: ApplicationFiled: March 14, 2013Publication date: September 18, 2014Inventors: Woo Lee, Jenny Zilberberg, David Samuel Siegel, Peter Tolias, Hongjun Wang, Wenting Zhang
-
Patent number: 8828435Abstract: A buccal delivery system capable of being blended in a normal dry powder process and compressed using a standard tabletting machine, said buccal delivery system comprising a matrix of: (a) an effective amount of one or more active ingredients; (b) an amount of one or more polyethylene glycols or derivatives thereof having a molecular weight between 1000 to 8000 sufficient to provide the required hardness and time for dissolution of the matrix; (c) 0.05-2% by weight of the total matrix of one or more suspending agents; (d) 0.05-2% by weight of the total matrix of one or more flowing agents; and (e) 0.05-2% by weight of the total matrix of one or more sweeteners.Type: GrantFiled: February 4, 2011Date of Patent: September 9, 2014Assignee: Lingual Consegna Pty LtdInventors: Ernest Alan Hewitt, Richard James Stenlake
-
Patent number: 8822436Abstract: Oral dosage forms of bisphosphonate compounds, such as zoledronic acid, can be used to treat or alleviate pain or related conditions. The oral bioavailability of zoledronic acid can be enhanced by administering the zoledronic acid in the disodium salt form.Type: GrantFiled: June 20, 2014Date of Patent: September 2, 2014Assignee: Antecip Bioventures II LLCInventor: Herriot Tabuteau
-
Publication number: 20140234210Abstract: Metal-bisphosphonate nanoparticles are disclosed. Also disclosed are pharmaceutical compositions including the metal-bisphosphonate nanoparticles, methods of preparing the metal-bisphosphonate nanoparticles and materials comprising the nanoparticles, and methods of using the compositions to treat cancer or bone-related disorders (e.g., bone-resorption-related diseases, osteoporosis, Paget's disease, and bone metastases) and as imaging agents.Type: ApplicationFiled: July 9, 2012Publication date: August 21, 2014Applicant: The University of North Carolina at Chapel HillInventors: Wenbin Lin, Demin Liu, Joseph Della Rocca, Stephanie A. Kramer, Christopher Y. Poon
-
Patent number: 8802658Abstract: Oral dosage forms of bisphosphonate compounds, such as zoledronic acid, can be used to treat or alleviate pain or related conditions. The oral bioavailability of zoledronic acid can be enhanced by administering the zoledronic acid in the disodium salt form.Type: GrantFiled: October 25, 2013Date of Patent: August 12, 2014Assignee: Antecip Bioventures II LLCInventor: Herriot Tabuteau
-
Publication number: 20140220128Abstract: A solid dosage form comprises coated particles of bisphosphonate or a pharmaceutically acceptable analogue or derivative thereof.Type: ApplicationFiled: April 14, 2014Publication date: August 7, 2014Applicant: Arrow International LimitedInventors: Peter Persicaner, Judy Craig
-
Publication number: 20140205648Abstract: The present invention relates to methods for in situ treatment of malignant cells from a cancer associated with bone. In one method, the treatment is for a primary cancer and entails positioning an implant containing and/or coated with at least one active agent for treating malignant cells directly in/on or indirectly among/near (e.g., by placing the implant in an area immediately proximal to) a site containing the malignant cells. In another method, the treatment includes positioning an implant containing and/or coated with at least one active agent for treating malignant cells directly in/on or indirectly among/near (e.g., by placing the implant in an area immediately proximal to) a surgical site from which malignant cells were previously removed/excised.Type: ApplicationFiled: April 3, 2014Publication date: July 24, 2014Applicant: DePuy Synthes Products, LLCInventor: Maria Maccecchini
-
Patent number: 8772268Abstract: Bisphosphonamidate prodrugs of therapeutic bisphosphonate compounds and uses thereof to treat diseases are described.Type: GrantFiled: April 27, 2011Date of Patent: July 8, 2014Assignee: The Johns Hopkins UniversityInventors: Caren Laura Freel Meyers, Marie Webster
-
Patent number: 8772267Abstract: The invention is directed to a method of treating chronic spinal mechanical pain by intravenous administration to a subject in need of chronic spinal mechanical pain relief of an effective amount of bisphosphonate.Type: GrantFiled: December 8, 2010Date of Patent: July 8, 2014Assignee: New York UniversityInventor: Marco Pappagallo
-
Patent number: 8765674Abstract: The invention relates to a combined pharmaceutical preparation comprising parathyroid hormone and a bone resorption inhibitor, said preparation being adapted for (a) the administration of parathyroid hormone during a period of approximately 6 to 24 months; (b) after the administration of parathyroid hormone has been terminated, the administration of a bone resorption inhibitor during a period of approximately 12 to 36 months.Type: GrantFiled: February 24, 2012Date of Patent: July 1, 2014Assignee: NPS Pharmaceuticals, Inc.Inventors: John Dietrich, Sverker Ljunghall, Sven Sjogren
-
Patent number: 8748410Abstract: The present invention is directed to a method for treating aneurysms in vascular tissue. The method includes administering a bisphosphonate compound to a subject in an amount which is effective against the formation or progression of aneurysm, or which is effective to induce regression of an established aneurysm. In alternative methods, an anti-RANKL neutralizing antibody is administered to the subject to achieve analogous anti-aneurysm effect. The methods of particular advantage in the treatment of subjects having an abdominal aortic aneurysm, a relatively common, and life-threatening, condition.Type: GrantFiled: September 9, 2011Date of Patent: June 10, 2014Assignee: Wisconsin Alumni Research FoundationInventors: Dai Yamanouchi, K. Craig Kent, Bo Liu
-
Publication number: 20140147484Abstract: A composition containing a macrophage inhibitor may be administered in an effective amount to prevent, inhibit or reduce restenosis, thrombus or aneurysm formation in implanted polymeric vascular grafts. The composition may be administered prior to vascular graft implantation, at the same time as vascular graft implantation, following vascular graft implantation, or any combination thereof. Examplary macrophage inhibitors include bisphosphonates, anti-folate drugs and antibodies, preferably in a controlled release or liposomal formulation.Type: ApplicationFiled: June 20, 2012Publication date: May 29, 2014Applicant: YALE UNIVERSITYInventors: Christopher K. Breuer, Tarek Fahmy
-
Patent number: 8697124Abstract: A solid dosage form comprises coated particles of bisphosphonate or a pharmaceutically acceptable analogue or derivative thereof.Type: GrantFiled: August 24, 2007Date of Patent: April 15, 2014Assignee: Arrow International LimitedInventors: Peter Persicaner, Craig Judy
-
Publication number: 20140080775Abstract: The present invention is directed toward a method of treating a subject for a condition mediated by aberrant Wnt/?-catenin signaling by selecting a subject with a condition mediated by aberrant Wnt/?-catenin signaling and administering to the selected subject at least one compound selected from the group consisting of those set forth in Table 1, Table 2, Table 3, and a pharmaceutically acceptable salt thereof. A method of similarly modulating the Wnt/?-catenin pathway in a subject is also discussed.Type: ApplicationFiled: November 18, 2013Publication date: March 20, 2014Applicants: UNIVERSITY OF WASHINGTON, The General Hospital Corporation, MASSACHUSETTS INSTITUTE OF TECHNOLOGYInventors: Randall T. Moon, Travis L. Biechele, Nathan D. Camp, Stephen Haggarty, Daniel Fass
-
Publication number: 20140072571Abstract: Disclosed are methods of identifying subjects with osteoporosis or osteopenia, subjects at risk for developing osteoporosis, osteopenia, and bone fractures, methods of evaluating the effectiveness of osteoporosis treatments in subjects with osteoporosis or osteopenia, and methods of selecting therapies for treating osteoporosis or osteopenia, using biomarkers.Type: ApplicationFiled: March 11, 2013Publication date: March 13, 2014Applicant: TETHYS BIOSCIENCE, INC.Inventors: Mickey S. Urdea, Michael P. McKenna, Patrick A. Arensdorf
-
Publication number: 20140057877Abstract: This invention relates to a process of synthesis and composition of open chain (ring), closed ring, linear branched and or substituted polyamines, polyamine derived tyrosine phosphatase inhibitors and PPAR partial agonists/partial antagonists via a series of substitution reactions and optimizing the bioavailability and biological activities of the compounds. Polyamines prevent the toxicity of neurotoxins and diabetogenic toxins including paraquat, methyphenyl pyridine radical, rotenone, diazoxide, streptozotocin and alloxan.Type: ApplicationFiled: October 18, 2011Publication date: February 27, 2014Inventors: Michael A. Murphy, Mitchell R. Malachowski
-
Publication number: 20140045794Abstract: The present invention relates to phosphonate compounds, compositions containing them, processes for obtaining them, and their use for treating a variety of medical disorders, e.g., osteoporosis and other disorders of bone metabolism, cancer, viral infections, and the like.Type: ApplicationFiled: October 21, 2013Publication date: February 13, 2014Applicant: The Regents of the University of CaliforniaInventors: Karl Y. Hostetler, James R. Beadle
-
Publication number: 20140045797Abstract: The present invention concerns conjugate compounds comprising a bisphosphonate covalently bonded to a prostatic acid phosphatase inhibitor and compositions comprising such conjugates. Methods for treating and inhibiting prostate cancer bone metastases, and determining whether a conjugate is useful for such treatment are also provided. In some instances, the bisphosphonate is alendronate, and it is covalently bonded to either tartaric acid or glyceric acid.Type: ApplicationFiled: October 16, 2013Publication date: February 13, 2014Applicants: LEHIGH UNIVERSITY, MOUNT SINAI SCHOOL OF MEDICINEInventors: ALEXANDER KIRSCHENBAUM, ALICE C. LEVINE, STEVEN L. REGEN, VACLAV JANOUT
-
Publication number: 20140039454Abstract: Methods of therapeutically treating osteoarthritis in a joint are disclosed. These methods aim to prevent the progression of osteoarthritis of a joint by treating the subchondral bone to heal, or delay the onset or progression of, bone marrow edema or lesions in the subchondral bone region of the joint. Associated devices and instruments for such subchondral treatment are also provided.Type: ApplicationFiled: August 5, 2013Publication date: February 6, 2014Applicant: Zimmer GmbH, Inc.Inventor: Peter F. SHARKEY
-
Publication number: 20140011774Abstract: This invention provides pharmaceutical compositions comprising combination of SARM compounds and antiresorptive agents such as SERM compounds, including, inter-alia, Raloxifene, and uses thereof for treating osteoporosis and associated diseases.Type: ApplicationFiled: March 13, 2013Publication date: January 9, 2014Inventors: James T. DALTON, Duane D. Miller, Juhyun Kim, Mitchell S. Steiner
-
Patent number: 8609638Abstract: The invention provides compounds, compositions, and methods for studying the Rohmer pathway and for treating bacterial infections or parasitic infections. The parasitic infection can be a protozoan infection, such as malaria. The compounds and compositions can also be used as antibiotics, for example, to kill bacteria or parasites, or to inhibit bacterial or parasite growth. The invention further provides inhibitors of isoprenoid biosynthesis enzymes, and methods of inhibiting the activity of isoprenoid biosynthesis enzymes. The compounds can be, for example, alkynes or allenes that bind to a unique Fe of an Fe4S4 cluster of an isoprenoid biosynthesis enzyme.Type: GrantFiled: October 8, 2010Date of Patent: December 17, 2013Assignee: The Board of Trustees of the University of IllinoisInventors: Eric Oldfield, Ke Wang, Weixue Wang, Yonghui Zhang
-
Publication number: 20130315981Abstract: The present invention is a method of increasing lipolysis in an adipose tissue of a mammal comprising delivering to macrophages at the adipose tissue of the mammal an effective amount of an agent which reduces the concentration of macrophages at the adipose tissue of the mammal, thereby increasing lipolysis in the adipose tissue of the mammal.Type: ApplicationFiled: June 22, 2011Publication date: November 28, 2013Applicant: The Trustees of Columbia University in the City of New YorkInventors: Anthony W. Ferrante, JR., Aliki Kosteli
-
Publication number: 20130287749Abstract: The present invention relates to novel phosphonic acid formulations and to their use as slug and snail baits, and to the corresponding slug and snail baits, to a process for their preparation and to their use for controlling slugs and snails.Type: ApplicationFiled: September 30, 2011Publication date: October 31, 2013Applicant: BAYER INTELLECTUAL PROPERTY GMBHInventors: Wolfgang Wirth, Margit Doth, Sybille Lamprecht, Hubert Schmeer
-
Publication number: 20130244962Abstract: Several parasites responsible for mammalian diseases are dependent on cysteine protease for various life-cycle functions. Inhibition or decreasing function of these proteases can be useful in the treatment and/or prevention of these parasitic diseases including; toxoplasmosis, malaria, African trypanosomiasis, Chagas disease, leishmaniasis, schistosomiasis, amebiasis, giardiasis, clonorchiasis, opisthorchiasis, paragonimiasis, fasciolopsiasis, lymphatic filariasis, onchocerciasis, dracunculiasis, ascariasis, trichuriasis, stronglyoidiasis, trichostrongyliasis, trichomoniasis or cestodiasis.Type: ApplicationFiled: April 11, 2013Publication date: September 19, 2013Applicant: Merck Frosst Canada Ltd.Inventors: Elise ISABEL, Christopher MELLON, Christian BEAULIEU
-
Patent number: 8518914Abstract: The invention relates to the use of a hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor and of a farnesyl-pyrophosphate synthase inhibitor, or of one of their associated physiologically acceptable salts, in the preparation of a composition, particularly a pharmaceutical composition, for use in the treatment of human or animal, pathological or nonpathological situations related to the accumulation and/or the persistence of prenylated proteins in cells, such as during progeria (Hutchinson-Gilford syndrome), restrictive dermopathy or physiological aging.Type: GrantFiled: July 5, 2007Date of Patent: August 27, 2013Assignees: Universite de la Mediterranee AIX-Marseille II, Association Francaise Contre les Myophathies (AFM), Assistance Publique Hopitaux de Marseille, Universidad de OviedoInventors: Nicolas Levy, Pierre Cau, Carlos Lopez-Otin
-
Publication number: 20130195856Abstract: The present invention provides a method of promoting local bone growth by administering a therapeutic amount of a Sost antagonist to a mammalian patient in need thereof. Preferably, the Sost antagonist is an antibody or FAB fragment selectively recognizing any one of SEQ ID NOS: 1-23. The Sost antagonist may be coadministered together or sequentially with a matrix conducive to anchoring new bone growth. Orthopedic and Periodontal devices comprising an implantable portion adapted to be permanently implanted within a mammalian body and bearing an external coating of a Sost antagonist are also disclosed, as it a method of increasing bone density by administering to a mammalian patient a therapeutic amount of a Sost antagonist together with an antiresorptive drug.Type: ApplicationFiled: March 12, 2013Publication date: August 1, 2013Applicant: OSSIFI INC.Inventor: OssiFi Inc.
-
Publication number: 20130149355Abstract: Isolatable, hydroxyapatite-targeting polymeric structures, and biologically active conjugates thereof, are provided. The polymeric structure includes a linear or branched water-soluble and non-peptidic polymer backbone, such as a PEG backbone, having at least two termini, a first terminus being covalently bonded to a hydroxyapatite-targeting moiety, such as a bisphosphonate, and a second terminus covalently bonded to a chemically reactive group, wherein said chemically reactive group is protected or unprotected. Methods of preparing and using hydroxyapatite-targeting polymeric structures, and biologically active conjugates thereof, are also provided.Type: ApplicationFiled: February 11, 2013Publication date: June 13, 2013Applicant: NEKTAR THERAPEUTICSInventor: NEKTAR THERAPEUTICS
-
Publication number: 20130137571Abstract: The present invention relates to a novel crystalline modification of fipronil, to a process for the preparation of the same, to pesticidal and parasiticidal mixtures and compositions comprising said crystalline modification and to their use for combating pests and parasites.Type: ApplicationFiled: January 22, 2013Publication date: May 30, 2013Applicant: BASF SEInventors: Heidi Emilia SAXELL, Peter ERK, Claude TARANTA, Thomas KROEHL, Gerhard COX, Martin SUKOPP, Stefan SCHERER, Antti OJALA, Gautam R. DESIRAJU, Rahul BANERJEE, Prashant M. BHATT
-
Publication number: 20130129814Abstract: The present invention relates to the regional delivery of therapeutic agents for the treatment of vascular diseases wherein regional delivery refers to delivery of a therapeutically effective amount of the therapeutic agent to an area of the vessel that includes not only afflicted tissue but non-afflicted tissue at the periphery of the afflicted tissue as well.Type: ApplicationFiled: December 21, 2012Publication date: May 23, 2013Applicant: ABBOTT CARDIOVASCULAR SYSTEMS INC.Inventor: ABBOTT CARDIOVASCULAR SYSTEMS INC.
-
Publication number: 20130116215Abstract: The invention features novel pharmaceutical combinations useful for the treatment of neurological diseases, specifically neurodegenerative diseases. The novel pharmaceutical combinations of the invention demonstrate additive or synergistic effect in silico and in vivo. The invention also relates to methods of treatment of neurological and neurodegenerative diseases including the pharmaceutical combinations of the invention.Type: ApplicationFiled: October 25, 2012Publication date: May 9, 2013Inventors: Mireia Coma, Patrick Aloy, Albert Pujol, Xavier Gomis, Baldomero Oliva, Alberto Lleó, José Manuel Mas
-
Publication number: 20130096091Abstract: The present invention relates to a composition for preventing or treating osteoporosis which comprises an ibandronic acid, or a pharmaceutically acceptable salt thereof, or a hydrate thereof, and vitamin D. The present invention relates to a composition for preventing or treating osteoporosis which has uniform medicinal effects by minimizing the differences in physical properties between ibandronic acid, or the pharmaceutically acceptable salt thereof, or the hydrate thereof, and vitamin D.Type: ApplicationFiled: June 3, 2011Publication date: April 18, 2013Inventors: Sang-Geun Park, Chang-Kyoo Lee, Tae-Won Lee
-
Publication number: 20130090311Abstract: Bisphosphonamidate prodrugs of therapeutic bisphosphonate compounds and uses thereof to treat diseases are described.Type: ApplicationFiled: April 27, 2011Publication date: April 11, 2013Applicant: The Johns Hopkins UniversityInventors: Caren Laura Freel Meyers, Marie Webster
-
Publication number: 20130090371Abstract: The present invention generally relates to compositions and kits comprising a ?2-AR agonist and a modulator of a ?2-AR regulator gene, where the modulator of the ?2-AR regulator gene inhibits the internalization and/or degradation of the ?2-ad-renergic receptor (?2-AR). More specifically, the present invention relates to the use of an agonist of ?2-adrenergic receptor (?2-AR) and an agent which inhibits agonist induced ?2-adrenergic receptor (?2-AR) internalization and/or degradation in method for the treatment of a respiratory disorder in a subject.Type: ApplicationFiled: April 20, 2011Publication date: April 11, 2013Applicant: PRESIDENT AND FELLOWS OF HARVARD COLLEGEInventor: Quan Lu
-
Publication number: 20130065850Abstract: Alterations of certain metabolite concentrations and fluxes that occur in response to viral infection are described. Host cell enzymes in the involved metabolic pathways are selected as targets for intervention; i.e., to restore metabolic flux to disadvantage viral replication, or to further derange metabolic flux resulting in “suicide” of viral-infected cells (but not uninfected cells) in order to limit viral propagation. While any of the enzymes in the relevant metabolic pathway can be selected, pivotal enzymes at key control points in these metabolic pathways are preferred as candidate antiviral drug targets. Inhibitors of these enzymes are used to reverse, or redirect, the effects of the viral infection. Drug candidates are tested for antiviral activity using screening assays in vitro and host cells, as well as in animal models. Animal models are then used to test efficacy of candidate compounds in preventing and treating viral infections. The antiviral activity of enzyme inhibitors is demonstrated.Type: ApplicationFiled: April 3, 2012Publication date: March 14, 2013Applicant: THE TRUSTEES OF PRINCETON UNIVERSITYInventors: Josh MUNGER, Bryson BENNETT, Thomas SHENK, Joshua RABINOWITZ
-
Publication number: 20130045950Abstract: The present invention relates to phosphonate compounds, compositions containing them, processes for obtaining them, and their use for treating a variety of medical disorders, e.g., osteoporosis and other disorders of bone metabolism, cancer, viral infections, and the like.Type: ApplicationFiled: October 4, 2012Publication date: February 21, 2013Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventor: THE REGENTS OF THE UNIVERSITY OF CALIF
-
Patent number: 8377910Abstract: The invention relates to sphingosine derivative compounds, like D-erythro-sphingosine 1-phosphate (S1P), to be used as immunomodulators in a microbicidal treatment of infections derived from bacteria and specifically Mycobacterium tuberculosis. Such compounds are characterized in that they stimulate macrophagic Phospholipase D (PLD) (FIG. 1). The invention further relates to pharmaceutical compositions containing sphingosine derivative compounds and diagnostic methods for the preparation thereof. Further objects of the invention are methods of inducing or restoring the microbicidal activity in vitro of macrophages for monitoring the efficiency of phagocytosis and degradation processes performed by the same and assay methods suitable to evaluate therapeutic effectiveness of candidate microbicides.Type: GrantFiled: November 21, 2002Date of Patent: February 19, 2013Assignee: Universita Degli Studi di Roma “Tor Vergata”Inventors: Maurizio Fraziano, Sanjay Kumar Garg, Antonio Ciaramella, Giovanni Auricchio, Elisabetta Volpe, Angelo Martino, Patrizia Morena Baldihi, Paolo De Vito, Domenico Galati, Vittorio Colizzi
-
Publication number: 20130035314Abstract: Methods of and kits for determining the pharmacogenetic, pharmacokinetic and cellular basis of bisphosphonate-induced osteonecrosis of the jaw (BONJ) involve associating particular proteins and particular single nucleotide polymorphisms with a risk for developing BONJ after receiving bisphosphonate treatment. Methods and kits for identifying the genetic basis for a patient's predisposition to BONJ, and methods of identifying patients who are prone to develop BONJ following bisphosphonate administration provide for the development of a tool for physicians to prescribe treatment protocols for BONJ patients based on the patients' genomes (“personal/tailored medicine”). A haplotype tagging SNP approach was used to analyze candidate genes involved in bone absorption and destruction and to examine the influence of genetic variants on the susceptibility of BONJ. Bone biomarkers of BONJ were examined using molecular cell techniques.Type: ApplicationFiled: December 13, 2010Publication date: February 7, 2013Inventors: Joseph Katz, Taimour Y. Langaee
-
Publication number: 20130022645Abstract: Disclosed is an oral bisphosphonate formulation characterized by an enhanced clinical bioavailability of bisphosphonate and by the use of phytic acid and a delayed release means for releasing bisphosphonate at a site of the lower gastrointestinal tract. Having a low phytic acid content, the oral bisphosphonate formulation guarantees high safety to the patient. Moreover, the oral formulation is designed to allow the patients to take the medicament, together with food intake, at a bioavailability as high as that of an empty stomach, thus improving the convenience of drug administration for the patient. Therefore, the oral formulation is expected to provide higher therapeutic effects for osteoporosis.Type: ApplicationFiled: October 19, 2011Publication date: January 24, 2013Applicant: DONG-A PHARM. CO., LTD.Inventors: Mi-Won SON, Sun-Woo JANG, Jeong-Soo KIM, Dong-Sung RYU, Wan-Sung KU
-
Publication number: 20120322767Abstract: Compositions for pharmaceutical use are described, comprising bisphosphonates and vitamin D in high concentration, destined to the intramuscular and subcutaneous intermittent administration for treatment of bone and skeletal system diseases, particularly osteoporosis, and sensitive cancers. These formulations are characterized by the use of a lipid and phospholipid emulsion at high concentration, having optimal carrier and solvent power for both the pharmacologically active components.Type: ApplicationFiled: November 25, 2010Publication date: December 20, 2012Inventor: Tiberio Bruzzese
-
Patent number: 8324189Abstract: A method of intravenously administering a bisphosphonate to a patient in need of bisphosphonate treatment comprising intravenously administering 4 mg of 2-(imidazol-1yl)-1-hydroxyethane-1,1-diphosphonic acid (zoledronic acid) or a pharmaceutically acceptable salt thereof over a period of 15 minutes to a patient in need of said treatment.Type: GrantFiled: November 8, 2006Date of Patent: December 4, 2012Assignee: Novartis Pharmaceuticals CorporationInventors: Bruno Galli, Horst F Schran, John J Seaman
-
Patent number: 8323687Abstract: The invention relates to medicine and pharmacology, and represents a pharmaceutical composition for the treatment of bone resorption of various etiology comprising, as the biologically active ingredient, liposomes with biphosphonates in gel dosage form suitable for transdermal delivery of biphosphonates and effective local therapy. Using this composition, methods for the prevention and treatment of osteoporosis, Paget's disease, patoplogical fractures associated with oncological diseases, and some other pathological processes associated with bone resorption and reparation are proposed.Type: GrantFiled: March 18, 2008Date of Patent: December 4, 2012Inventors: Aleksander Vladimirovich Dikovskiy, Boris Anatolievich Rudoy, Oleg Valentinovich Dorozhko
-
Publication number: 20120288485Abstract: A formulation, composition or combination of substances comprising jasmonate for modulating melatonin production and/or calcification of a pineal gland and/or modulation and/or treatment of age-related neurodegeneration in a subject, particularly in a mammalian subject and more particularly in a human subject and use of jasmonate for modulating melatonin production and/or calcification of a pineal gland and/or modulation and/or treatment of age-related neurodegeneration is provided.Type: ApplicationFiled: May 9, 2012Publication date: November 15, 2012Applicant: Broady Health Sciences, LLC.Inventor: Brunde Broady
-
Publication number: 20120231010Abstract: The present invention provides a method of promoting bone growth in a subject in need thereof, by administering to the subject a therapeutically effective amount of a compound of Formula I. The compounds include the salts, hydrates and isomers thereof. The present invention also provides methods for the treatment of renal disease and cancer.Type: ApplicationFiled: May 17, 2012Publication date: September 13, 2012Applicant: OsteoGeneX Inc.Inventors: Debra Ellies, William Rosenberg
-
Publication number: 20120196835Abstract: The invention provides compounds, compositions, and methods for studying the Rohmer pathway and for treating bacterial infections or parasitic infections. The parasitic infection can be a protozoan infection, such as malaria. The compounds and compositions can also be used as antibiotics, for example, to kill bacteria or parasites, or to inhibit bacterial or parasite growth. The invention further provides inhibitors of isoprenoid biosynthesis enzymes, and methods of inhibiting the activity of isoprenoid biosynthesis enzymes. The compounds can be, for example, alkynes or allenes that bind to a unique Fe of an Fe4S4 cluster of an isoprenoid biosynthesis enzyme.Type: ApplicationFiled: October 8, 2010Publication date: August 2, 2012Inventors: Eric Olafield, Ke Wang, Weixue Wang, Yonghui Zhang
-
Patent number: 8232261Abstract: The present invention provides a method of reducing phytotoxicity or plant injury at a crop plant locus caused by a herbicide application at the locus which method includes applying to the crop plant locus a chloronicotinyl insecticide before the herbicide application.Type: GrantFiled: July 18, 2003Date of Patent: July 31, 2012Assignee: Bayer CropScience LPInventor: Michael R. Schwarz
-
Publication number: 20120178720Abstract: The present invention refers to bisphosphonate and phosphonate/phosphate compounds of Formulae I and its use as inhibitors of aSMase enzyme activity.Type: ApplicationFiled: August 19, 2010Publication date: July 12, 2012Inventors: Christoph Arenz, Anke Gundula Roth, Stefan Uhlig, Daniela Drescher